Ironwood Pharmaceuticals Inc. has leased an additional 50,000 square feet at its 301 Binney St. laboratory research facility in Cambridge.

Ironwood leased the additional space near its existing premises in Cambridge’s Kendall Square. The expansion will increase Ironwood’s occupancy in the five-story facility to approximately 164,000 square feet.

"After almost three years as one of BioMed’s premier privately held life science tenants, Ironwood recently completed its initial public offering, continuing on its path of strong capital raising success driven by its world-class research and development team and promising drug candidates," said Alan D. Gold, BioMed’s chairman and chief executive officer. "We congratulate the Ironwood team on this accomplishment and are pleased to expand our relationship with them as they continue to discover, develop, manufacture and commercialize their drug pipeline to address important human needs. We look forward to supporting their cutting-edge technologies and entrepreneurship by continuing to provide them the best-in-class research center at 301 Binney."

The 301 Binney St. property is owned through BioMed’s joint venture with institutional investors advised by Prudential Real Estate Investors.